Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year

被引:259
作者
Ahrén, B
Pacini, G
Foley, JE
Schweizer, A
机构
[1] Lund Univ, Dept Med, SE-22184 Lund, Sweden
[2] Italian Natl Res Council, Inst Biomed Engn, Metab Unit, Padua, Italy
[3] Novartis Pharmaceut, E Hanover, NJ USA
[4] Novartis Pharmaceut, Basel, Switzerland
关键词
D O I
10.2337/diacare.28.8.1936
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - To examine the effects of dipeptidyl peptidase-IV (DPP-4) inhibition on meal-related P-cell function and insulin sensitivity over 52 weeks in type 2 diabetes. RESEARCH DESIGN AND METHODS - In a 12-week core study, placebo (n = 5 1) or vildagliptin (n = 56; 50 mg OD) was added to metformin treatment (1.5-3.0 mg/day). A 40-week extension followed in 71 patients. Meal tests were performed at 0, 12, 24, and 52 weeks; glucose, insulin, and C-peptide were evaluated. RESULTS - in subjects completing 52 weeks with participation in all meal tests (n = 57), HbA(1c) (AlC) decreased in the vildagliptin/metformin group (VM group, n = 31) but increased in the placebo/metformin group (PM group, It = 26; between-group difference - 1.0 +/- 0.2%; P < 0.001; baseline of all subjects combined 7.7 +/- 0.1%). Also, fasting glucose decreased in the VM group but increased in the PM group (difference -0.9 +/- 0.3 mmol/l, P = 0.016; baseline 9.8 +/- 0.3 mmol/l). Insulin secretion (postmeal suprabasal area under the 0- to 30-min C-peptide curve divided by the 30-min increase in glucose) was increased in the VM group but was reduced in the PM group (difference + 0.011 +/- 0.03 pmol/l 30 min/mmol/l, P = 0.018; baseline 0.036 +/- 0.02). Insulin sensitivity during meal ingestion (oral glucose insulin sensitivity) increased in the VM group but was not altered in the PM group (difference + 27 +/- 4 ml center dot min(-1). m(-2), p = 0.036; baseline 246 - 6). Insulin secretion related to insulin sensitivity (adaptation index) increased in the VM group but decreased in the PM group (difference + 3.2 +/- 1.0, P = 0.040; baseline 9.1 +/- 0.5). The change in adaptation index correlated to the change in AlC (r = -0.39, P = 0.004). CONCLUSIONS - This study presents evidence that DPP-4 inhibition by vildagliptin when added to metformin in type 2 diabetes over 52 weeks improves beta-cell function along with improved postmeal insulin sensitivity.
引用
收藏
页码:1936 / 1940
页数:5
相关论文
共 24 条
[1]   Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus [J].
Ahren, B ;
Larsson, H ;
Holst, JJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (02) :473-478
[2]   Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes [J].
Ahrén, B ;
Landin-Olsson, M ;
Jansson, PA ;
Svensson, M ;
Holmes, D ;
Schweizer, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (05) :2078-2084
[3]   Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes [J].
Ahrén, B ;
Gomis, R ;
Standl, E ;
Mills, D ;
Schweizer, A .
DIABETES CARE, 2004, 27 (12) :2874-2880
[4]   Impaired adaptation of first-phase insulin secretion in postmenopausal women with glucose intolerance [J].
Ahren, B ;
Pacini, G .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1997, 273 (04) :E701-E707
[5]   Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes [J].
Ahrén, B ;
Simonsson, E ;
Larsson, H ;
Landin-Olsson, M ;
Torgeirsson, H ;
Jansson, PA ;
Sandqvist, M ;
Båvenholm, P ;
Efendic, S ;
Eriksson, JW ;
Dickinson, S ;
Holmes, D .
DIABETES CARE, 2002, 25 (05) :869-875
[6]   Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies [J].
Ahrén, B ;
Pacini, G .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2004, 150 (02) :97-104
[7]   Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats [J].
Balkan, B ;
Kwasnik, L ;
Miserendino, R ;
Holst, JJ ;
Li, X .
DIABETOLOGIA, 1999, 42 (11) :1324-1331
[8]   PHYSIOLOGIC EVALUATION OF FACTORS CONTROLLING GLUCOSE-TOLERANCE IN MAN - MEASUREMENT OF INSULIN SENSITIVITY AND BETA-CELL GLUCOSE SENSITIVITY FROM THE RESPONSE TO INTRAVENOUS GLUCOSE [J].
BERGMAN, RN ;
PHILLIPS, LS ;
COBELLI, C .
JOURNAL OF CLINICAL INVESTIGATION, 1981, 68 (06) :1456-1467
[9]   Inhibitors of dipeptidyl peptidase IV:: a novel approach for the prevention and treatment of Type 2 diabetes? [J].
Deacon, CF ;
Ahrén, B ;
Holst, JJ .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (09) :1091-1102
[10]   Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans [J].
Holst, JJ ;
Gromada, J .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2004, 287 (02) :E199-E206